Placeholder

Obinutuzumab (Afutuzumab)

  • # LGM Pharma is a Obinutuzumab (Afutuzumab) CAS# 949142-50-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Obinutuzumab (Afutuzumab)
  • CAS #: 949142-50-1
  • Mode of Action:

    In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

  • Pharmacodynamics:

    Obinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.

  • Metabolism:

    Obinutuzumab is not metabolized by the liver.

  • Toxicity:

    The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.

  • ATC: L01XC15
  • DrugBank: DB08935
  • Formula: C6512H10060N1712O2020S44
  • Molecular Mass: 146100 daltons
  • Synonyms: Afutuzumab, Afutuzumab [Previous USAN], GA 101, GA101, Gazyva, huMAB(CD20), huMAB, huMABCD20, Obinutuzumab, Ro 5072759, Ro5072759, UNII-O43472U9X8
  • General Reference:

     

    1. FDA label.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements